The hypothesis that low-dose aspirin might eventually lower cancer risk after years of use appears unsupported in adults aged 70 years or older, according to new long-term data from the ASPREE trial.Over a median follow-up of 8.6 years, daily 100-mg aspirin was not associated with reduced cancer incidence and was associated with a higher risk […]
